Unmet Needs in Chronic Fibrosing ILD With Progressive Phenotype

A phase 2a trial of camlipixant, a selective P2X3 receptor antagonist, found that while the drug did not significantly reduce cough frequency in the overall population with refractory chronic cough, it produced meaningful improvements in patients with a higher baseline cough burden.

On this episode of Managed Care Cast, a research scholar at the Marron Institute of Urban Management at New York University discusses the latest findings in the Health of the Air report, which was presented at the recent American Thoracic Society 2021 International Conference.

Remote care reduced readmissions and improved functional outcomes in COPD in a recent study.

Courtney Blair, MD, discusses how COVID-19 has impacted patients with allergies and other respiratory conditions.

A new device was able to distinguish between mild and very severe chronic obstructive pulmonary disease (COPD).

Respiratory diseases made up the hospitalizations in older adults after they were exposed to wildfire smoke.